Siegfried Holding (SGFE.F) Stock Overview
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SGFE.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 100.00 |
| 52 Week High | CHF 114.35 |
| 52 Week Low | CHF 100.00 |
| Beta | 0.74 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -90.24% |
| 3 Year Change | -85.40% |
| 5 Year Change | n/a |
| Change since IPO | -43.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGFE.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | -0.3% |
| 1Y | -90.2% | -2.4% | 16.1% |
Return vs Industry: SGFE.F underperformed the US Life Sciences industry which returned -1.3% over the past year.
Return vs Market: SGFE.F underperformed the US Market which returned 16% over the past year.
Price Volatility
| SGFE.F volatility | |
|---|---|
| SGFE.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: SGFE.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SGFE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,891 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.
Siegfried Holding AG Fundamentals Summary
| SGFE.F fundamental statistics | |
|---|---|
| Market cap | US$4.29b |
| Earnings (TTM) | US$212.61m |
| Revenue (TTM) | US$1.67b |
Is SGFE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGFE.F income statement (TTM) | |
|---|---|
| Revenue | CHF 1.33b |
| Cost of Revenue | CHF 973.84m |
| Gross Profit | CHF 353.99m |
| Other Expenses | CHF 185.34m |
| Earnings | CHF 168.66m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | 3.85 |
| Gross Margin | 26.66% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 51.0% |
How did SGFE.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 11:05 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siegfried Holding AG is covered by 17 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |